Clinical trial
Study of Dasatinib in Children and Adolescents With Relapsed or Refractory…
NCT00306202 · Bristol-Myers Squibb, Industry · Completed
Key facts
| NCT number | NCT00306202 |
|---|---|
| Title | Study of Dasatinib in Children and Adolescents With Relapsed or Refractory Leukemia |
| Official title | Phase I Study of SRC/ABL Tyrosine Kinase Inhibitor Dasatinib [BMS-354825] in Children and Adolescents With Relapsed or Refractory Leukemia, Protocol ITCC 005 |
| Lead sponsor | Bristol-Myers Squibb, Industry |
| Collaborators | Innovative Therapies For Children with Cancer Consortium |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Leukemia |
| Intervention type | Drug |
| Interventions | Dasatinib |
| Enrollment | 63 |
| Start date | Mar 31, 2006 |
| Primary completion | May 31, 2011 |
| Completion | May 22, 2019 |
| First posted | Mar 23, 2006 |
| Last update posted | Feb 26, 2021 |
| Countries | Austria, France, Germany, Italy, Netherlands, United Kingdom |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: